Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Temanogrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 10/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Temanogrel SCHEMBL29436989 | 1.00 | HTR2A (1.00) | HTR2AKCNH2HTR2C | |
| Temanogrel SCHEMBL29538904 | 0.99 | HTR2A (0.98) | HTR2AKCNH2HTR2C | |
| Temanogrel SCHEMBL2037003 | 0.99 | HTR2A (0.98) | HTR2AKCNH2HTR2C | |
| Temanogrel SCHEMBL2015888 | 0.99 | HTR2A (0.98) | HTR2AKCNH2HTR2C | |
| Temanogrel SCHEMBL2039707 | 0.95 | HTR2A (0.91) | HTR2AKCNH2HTR2C | |
| Temanogrel SCHEMBL12802197 | 0.93 | HTR2A (0.86) | HTR2AKCNH2HTR2C | |
| SCHEMBL1166819 | 0.93 | HTR2A (0.86) | HTR2AKCNH2HTR2C | |
| SCHEMBL1166546 | 0.91 | HTR2A (1.00) | HTR2AKCNH2HTR2C | |
| SCHEMBL1167924 | 0.90 | HTR2A (1.00) | HTR2AKCNH2HTR2C | |
| SCHEMBL1166322 | 0.89 | HTR2A (0.82) | HTR2AKCNH2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| US-10781180-B2 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | claimed |
| US-20190263757-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-08-29 | — | — | US | claimed |
| US-20160304463-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2016-10-20 | — | — | US | claimed |
| US-RE45337-E1 | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | claimed |
| US-RE45336-E1 | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | claimed |
| US-20120252813-A1 | CRYSTALLINE FORMS OF CERTAIN 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, LLC | 2012-10-04 | — | — | US | claimed |
| US-8148418-B2 | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-04-03 | — | — | US | claimed |
| US-8148417-B2 | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-04-03 | — | — | US | claimed |
| WO-2011075596-A1 | CRYSTALLINE FORMS OF CERTAIN 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | WO | claimed |
| US-20110105456-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | claimed |
| EP-1978019-A1 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2008-10-08 | — | — | EP | claimed |
| EP-1833799-B1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT-2a SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2008-09-10 | — | — | EP | claimed |
| US-20070244086-A1 | 3-Phenyl-Pyrazole Derivatives as Modulators of the 5-Ht2A Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2007-10-18 | — | — | US | claimed |
| EP-1833799-A2 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT-2a SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2007-09-19 | — | — | EP | claimed |
| US-20070207994-A1 | 3-Phenyl-pyrazole derivatives as modulators of the 5-HT2a serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | claimed |
| WO-2006055734-A2 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | claimed |
| US-12611418-B2 | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | COMPASS PATHFINDER LIMITED (GB) | 2026-04-28 | — | — | US | disclosed |
| US-20250367223-A1 | METHODS FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | COMPASS PATHFINDER LIMITED (GB) | 2025-12-04 | — | — | US | disclosed |
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250360148-A1 | SOLID DISPERSIONS OF PSILOCYBIN | CYBIN IRL LIMITED (IE) | 2025-11-27 | — | — | US | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-12447164-B2 | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | COMPASS PATHFINDER LIMITED (GB) | 2025-10-21 | — | — | US | disclosed |
| US-12433904-B2 | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | COMPASS PATHFINDER LIMITED (GB) | 2025-10-07 | — | — | US | disclosed |
| US-20250302851-A1 | METHODS OF TREATING NEUROCOGNITIVE DISORDERS, CHRONIC PAIN AND REDUCING INFLAMMATION | COMPASS PATHFINDER LIMITED (GB) | 2025-10-02 | — | — | US | disclosed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| US-12377112-B2 | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation | COMPASS PATHFINDER LIMITED (GB) | 2025-08-05 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | Triastek, Inc. (CN) | 2025-06-10 | — | — | US | disclosed |
| EP-4512394-A2 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2025-02-26 | — | — | EP | disclosed |
| US-20250000881-A1 | TREATMENT OF TREATMENT RESISTANT DEPRESSION WITH PSILOCYBIN | COMPASS PATHFINDER LIMITED (GB) | 2025-01-02 | — | — | US | disclosed |
| US-20240408023-A1 | DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES | Triastek, Inc. (CN) | 2024-12-12 | — | — | US | disclosed |
| EP-4171518-B1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240390301-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-11-28 | — | — | US | disclosed |
| CN-119023851-A | Serum metabolic marker for early diagnosis of tibial dysplasia of broiler chickens and screening method and application thereof | 华南农业大学 | 2024-11-26 | — | — | CN | disclosed |
| US-20240342094-A1 | COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | Triastek, Inc. (CN) | 2024-10-17 | — | — | US | disclosed |
| EP-3302442-B1 | DOSAGE FORMS AND USE THEREOF | TRIASTEK INC (CN) | 2024-10-16 | — | — | EP | disclosed |
| US-12102721-B2 | Dosage forms of controlled release at specific gastrointestinal sites | Triastek, Inc. (CN) | 2024-10-01 | — | — | US | disclosed |
| US-20240252521-A1 | METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | COMPASS PATHFINDER LIMITED (GB) | 2024-08-01 | — | — | US | disclosed |
| US-12042562-B2 | 3D printing methods for compartmented pharmaceutical dosage forms | Triastek, Inc. (CN) | 2024-07-23 | — | — | US | disclosed |
| US-12006329-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240150453-A1 | METHODS OF PREDICTING RESPONSE TO ANTI-TNF BLOCKADE IN INFLAMMATORY BOWEL DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-09 | — | — | US | disclosed |
| EP-4364732-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2024-05-08 | — | — | EP | disclosed |
| CN-116077492-B | Application of glucagon receptor antagonist-3 in preparation of medicine for resisting gram positive bacterial infection | 华中科技大学协和深圳医院 | 2024-03-15 | — | — | CN | disclosed |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC | 2024-01-18 | — | — | US | disclosed |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC | 2024-01-18 | — | — | US | disclosed |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC | 2024-01-18 | — | — | US | disclosed |
| US-11865126-B2 | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | COMPASS PATHFINDER LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| WO-2023247665-A1 | SOLID DISPERSIONS OF PSILOCYBIN | CYBIN IRL LIMITED (IE) | 2023-12-28 | — | — | WO | disclosed |
| EP-4291239-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE. LTD. (SG) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230330117-A1 | METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | COMPASS PATHFINDER LIMITED (GB) | 2023-10-19 | — | — | US | disclosed |
| US-20230271983-A1 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2023-08-31 | — | — | US | disclosed |
| US-20230270665-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC | 2023-08-31 | — | — | US | disclosed |
| US-11738035-B2 | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | COMPASS PATHFINDER LIMITED (GB) | 2023-08-29 | — | — | US | disclosed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | disclosed |
| CN-116077492-A | Application of glucagon receptor antagonist-3 in preparation of medicine for resisting gram positive bacterial infection | 华中科技大学协和深圳医院 | 2023-05-09 | — | — | CN | disclosed |
| EP-4171518-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20230124137-A1 | METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | COMPASS PATHFINDER LIMITED (GB) | 2023-04-20 | — | — | US | disclosed |
| US-11623932-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| WO-2023028086-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-11564935-B2 | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | COMPASS PATHFINDER LIMITED (GB) | 2023-01-31 | — | — | US | disclosed |
| US-20230023092-A1 | TREATMENT OF DEPRESSION AND OTHER VARIOUS DISORDERS WITH PSILOCYBIN | HERCULES CAPITAL, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230000883-A1 | METHODS FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | HERCULES CAPITAL, INC. | 2023-01-05 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| WO-2022192419-A2 | METHODS OF TREATING INFLAMMATORY BOWEL DISEASE (IBD) WITH ANTI- TNF-BLOCKADE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-09-15 | — | — | WO | disclosed |
| US-11433022-B2 | Rapidly-orodispersible tablets having an in interior cavity | Aprecia Pharmaceuticals LLC (US) | 2022-09-06 | — | — | US | disclosed |
| WO-2022173333-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE. LTD. (SG) | 2022-08-18 | — | — | WO | disclosed |
| US-20220169668-A1 | METHODS OF TREATING NEUROCOGNITIVE DISORDERS, CHRONIC PAIN AND REDUCING INFLAMMATION | HERCULES CAPITAL, INC. | 2022-06-02 | — | — | US | disclosed |
| EP-3981392-A1 | CONTROLLED RELEASE DOSAGE FORM | Triastek, Inc. (CN) | 2022-04-13 | — | — | EP | disclosed |
| US-20220088041-A1 | METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | COMPASS PATHFINDER LIMITED (GB) | 2022-03-24 | — | — | US | disclosed |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | Triastek, Inc. (CN) | 2022-03-22 | — | — | US | disclosed |
| WO-2022056115-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022056115-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC (US) | 2022-03-17 | — | — | WO | disclosed |
| US-20220054409-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC | 2022-02-24 | — | — | US | disclosed |
| US-10781180-B2 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-10781180-B2 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190263757-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190263757-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20180186748-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATERS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. | 2018-07-05 | — | — | US | disclosed |
| US-9884863-B2 | STAT3 inhibitor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-02-06 | — | — | US | disclosed |
| US-9783502-B2 | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor | ARENA PHARMACEUTICALS, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170152260-A1 | STAT3 INHIBITOR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-06-01 | — | — | US | disclosed |
| US-9562002-B2 | STAT3 inhibitor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160304463-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304463-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304463-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160272591-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20150361031-A1 | STAT3 INHIBITOR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-12-17 | — | — | US | disclosed |
| US-9199940-B2 | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor | ARENA PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-8980891-B2 | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980891-B2 | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980891-B2 | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980891-B2 | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8785441-B2 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785441-B2 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785441-B2 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130296321-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130237540-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2013-09-12 | — | — | US | disclosed |
| US-20130237540-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2013-09-12 | — | — | US | disclosed |
| US-20130237540-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2013-09-12 | — | — | US | disclosed |
| US-8481535-B2 | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor | ARENA PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481535-B2 | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor | ARENA PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120252813-A1 | CRYSTALLINE FORMS OF CERTAIN 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, LLC | 2012-10-04 | — | — | US | disclosed |
| US-20120252813-A1 | CRYSTALLINE FORMS OF CERTAIN 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, LLC | 2012-10-04 | — | — | US | disclosed |
| US-20120252813-A1 | CRYSTALLINE FORMS OF CERTAIN 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, LLC | 2012-10-04 | — | — | US | disclosed |
| US-20120252813-A1 | CRYSTALLINE FORMS OF CERTAIN 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, LLC | 2012-10-04 | — | — | US | disclosed |
| WO-2011075596-A1 | CRYSTALLINE FORMS OF CERTAIN 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011075596-A1 | CRYSTALLINE FORMS OF CERTAIN 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011075596-A1 | CRYSTALLINE FORMS OF CERTAIN 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20110105456-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110105456-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110105456-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7884101-B2 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884101-B2 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884101-B2 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20100234380-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234380-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| EP-1978019-A1 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1978019-A1 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1833799-B1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT-2a SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2008-09-10 | — | — | EP | disclosed |
| EP-1833799-B1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT-2a SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070244086-A1 | 3-Phenyl-Pyrazole Derivatives as Modulators of the 5-Ht2A Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244086-A1 | 3-Phenyl-Pyrazole Derivatives as Modulators of the 5-Ht2A Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244086-A1 | 3-Phenyl-Pyrazole Derivatives as Modulators of the 5-Ht2A Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2007-10-18 | — | — | US | disclosed |
| EP-1833799-A2 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT-2a SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20070207994-A1 | 3-Phenyl-pyrazole derivatives as modulators of the 5-HT2a serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070207994-A1 | 3-Phenyl-pyrazole derivatives as modulators of the 5-HT2a serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070207994-A1 | 3-Phenyl-pyrazole derivatives as modulators of the 5-HT2a serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| WO-2006055734-A2 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006055734-A2 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (29 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006329-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | HTR2A 3472/4885KCNH2 4880/4885HTR2C 3971/4885 |
| US-20130237540-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR3A, HTR3B | HTR2A 4/4885KCNH2 1173/4885HTR2C 5/4885 |
| US-20240390301-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR5A | HTR2A 1/4885KCNH2 1160/4885HTR2C 2/4885 |
| US-20130296321-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | HTR2A, HTR5A, HTR2C | HTR2A 1/4885KCNH2 1312/4885HTR2C 3/4885 |
| US-20160304463-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR3A, HTR2A | HTR2A 3/4885KCNH2 867/4885HTR2C 5/4885 |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | CYP2D6, CYP3A5, CYP3A7 | HTR2A 3970/4885KCNH2 4857/4885HTR2C 4100/4885 |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | CYP2D6, CYP3A7, CYP3A5 | HTR2A 1560/4885KCNH2 4739/4885HTR2C 1537/4885 |
| US-20180186748-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATERS OF THE 5-HT2A SEROTONIN RECEPTOR | HTR2A, HTR5A, HTR2C | HTR2A 1/4885KCNH2 1638/4885HTR2C 3/4885 |
| US-20250360148-A1 | SOLID DISPERSIONS OF PSILOCYBIN | HTR2B, HTR2A, HTR2C | HTR2A 2/4885KCNH2 2576/4885HTR2C 3/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | HTR2A 3472/4885KCNH2 4880/4885HTR2C 3971/4885 |
| US-20120252813-A1 | CRYSTALLINE FORMS OF CERTAIN 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR3A, HTR2C, HTR2A | HTR2A 3/4885KCNH2 1110/4885HTR2C 2/4885 |
| US-20070207994-A1 | 3-Phenyl-pyrazole derivatives as modulators of the 5-HT2a serotonin receptor useful for the treatment of disorders related thereto | HTR5A, HTR3A, HTR3B | HTR2A 4/4885KCNH2 1173/4885HTR2C 5/4885 |
| US-20100234380-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | HTR2A, HTR5A, HTR2C | HTR2A 1/4885KCNH2 1312/4885HTR2C 3/4885 |
| US-20170152260-A1 | STAT3 INHIBITOR | STAT3, STAT1, STAT4 | HTR2A 3972/4885KCNH2 4870/4885HTR2C 3670/4885 |
| US-20230271983-A1 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | KIT, MACF1, IK | HTR2A 3877/4885KCNH2 2557/4885HTR2C 2993/4885 |
| US-20240342094-A1 | COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | CYP2D6, CYP3A5, CYP2F1 | HTR2A 1981/4885KCNH2 4728/4885HTR2C 1631/4885 |
| US-20190263757-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR3A, HTR2A | HTR2A 3/4885KCNH2 867/4885HTR2C 5/4885 |
| US-12611418-B2 | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | HTR1D, HTR1B, HTR2B | HTR2A 5/4885KCNH2 1334/4885HTR2C 4/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR2A 1/4885KCNH2 1707/4885HTR2C 5/4885 |
| US-11623932-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | HTR2A 3472/4885KCNH2 4880/4885HTR2C 3971/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | HTR2A 3472/4885KCNH2 4880/4885HTR2C 3971/4885 |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | ACE2, ACE, TMPRSS2 | HTR2A 826/4885KCNH2 1745/4885HTR2C 955/4885 |
| US-20110105456-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR3A, HTR3B | HTR2A 4/4885KCNH2 1173/4885HTR2C 5/4885 |
| US-12042562-B2 | 3D printing methods for compartmented pharmaceutical dosage forms | CYP3A43, HTR3D, CYP3A7 | HTR2A 1594/4885KCNH2 4787/4885HTR2C 402/4885 |
| US-10781180-B2 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | HTR5A, HTR3A, HTR2A | HTR2A 3/4885KCNH2 867/4885HTR2C 5/4885 |
| US-20160272591-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | HTR2A, HTR5A, HTR2C | HTR2A 1/4885KCNH2 1312/4885HTR2C 3/4885 |
| US-20070244086-A1 | 3-Phenyl-Pyrazole Derivatives as Modulators of the 5-Ht2A Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | HTR5A, HTR3A, HTR2A | HTR2A 3/4885KCNH2 867/4885HTR2C 5/4885 |
| US-20150361031-A1 | STAT3 INHIBITOR | STAT3, STAT1, STAT4 | HTR2A 3972/4885KCNH2 4870/4885HTR2C 3670/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | HTR2A 3360/4885KCNH2 4240/4885HTR2C 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.